Hanger — Investor Presentation (November 2013)
24 slides from Hanger's investor presentation, Nov 12, 2013
Slide 1: 150 Years of Empowering Human Potential - Investor Presentation
150 YEARS Investor Presentation of Empowering Human Potential. November 2013
Slide 2: Safe Harbor
SAFE HARBOR Except for the historical information contained herein, the matters discussed in this presentation constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. These include, but are not limited to,
Slide 3: Vision
VISION Be the partner of choice for products and services that enhance human physical capability. 2
Slide 4: Overview
OVERVIEW LTM net sales of $1.0 billion 2012 adjusted EBITDA* of $166 million 2012 adjusted EPS* of $1.80 Market capitalization of $1.1 billion Two segments: Patient Care – 83% of sales Products & Services – 17% of sales 3 CAGR 9.0% Growth in Adjusted Diluted EPS* Revenue Growth ($ in millions) * Rec
Slide 5: Key Investment Points
KEY INVESTMENT POINTS Compelling O&P industry growth dynamics Market leader in O&P patient care Proven organic growth and acquisition capabilities Solid financial position Steady margin enhancement Growth opportunities in adjacent markets 4
Slide 6: Patient Care
PATIENT CARE 5
Slide 7: Patient Care Profile
PATIENT CARE Over 740 O&P patient-care centers in 45 states Over 1,300 O&P certified and licensed clinicians Treat more than 1,000,000 patients annually Stand alone design, fabricate and fit Delivery through clinics, hospitals and physician offices Network management capability provides value to pay
Slide 8: Market Position - Patient Care
7 MARKET POSITION PATIENT CARE Only national or regional provider No other provider has more than 2% market share $4.3 Billion Total Addressable Market
Slide 9: Consistent Organic and Acquisition Growth
PATIENT CARE 8 CONSISTENT ORGANIC AND ACQUISITION GROWTH 5% - 9% Range
Slide 10: Compelling Growth Drivers
Disease and aging population Advancing technology Regulatory and healthcare reform Increased focus on costs and outcomes COMPELLING GROWTH DRIVERS 10 Sources: Company estimates; Wall Street Research; 2003–2006 National Health and Nutrition Examination Survey; National Institutes of Health; Amputee C
Slide 11: Patient Care Growth Opportunities
PATIENT CARE First to market with new technologies and products Linkia Network Management Diversification into new adjacent businesses O&P acquisitions Sales synergies across businesses Changing healthcare environment 11 GROWTH OPPORTUNITIES
Slide 12: Products & Services
PRODUCTS & SERVICES 12
Slide 13: Products & Services Profile
PRODUCT & SERVICES Distribution: Largest dedicated distributor of O&P devices and components Over 33,000 O&P related items 6 strategically located distribution facilities Manufacture and distribute therapeutic footwear Development and commercialization of new products Rehabilitative Solutions: Value
Slide 14: Products & Services Opportunities
PRODUCT & SERVICES Increase value proposition of product line Increase penetration of existing customer base Expand market presence geographically Expand into new channels Leverage product development and distribution capabilities Expand O&P fabrication operation to Independent O&P Providers 14 OPPO
Slide 15: Financial Overview
FINANCIAL OVERVIEW 15
Slide 16: Solid Performance and Stability
SOLID PERFORMANCE AND STABILITY Earnings and margin growth Substantial cash flow generation Strong balance sheet management Moderate leverage Consistent reduction of leverage 16
Slide 17: Leveraging Revenue Growth
LEVERAGING REVENUE GROWTH ($ in millions) 14.2% 15.0% 16.4% 17.0% Net Sales Adjusted EBITDA Margin* 17 * Reconciliation to GAAP provided on slides 23 and 24 CAGR 9.0% $753.1 $808.8 $907.8 $947.7 2009 2010 2011 2012
Slide 18: Growth in Adjusted Diluted EPS
GROWTH IN ADJUSTED DILUTED EPS* 18 Reconciliation to GAAP provided on slides 23 and 24
Slide 19: Steady Comparable Quarter Growth
STEADY COMPARABLE QUARTER GROWTH 2011 2012 2013 Adjusted EBITDA* ($ in millions) Revenues ($ in millions) Adjusted Earnings Per Diluted Share* 19 * Reconciliation to GAAP provided on slides 23 and 24 $0.15 $0.25 $0.35 $0.45 $0.55 $0.65 Q1 Q2 Q3 Q4 $190 $210 $230 $250 $270 $290 Q1 Q2 Q3 Q4 $15 $25 $3
Slide 20: Solid Cash Flow and Balance Sheet
SOLID CASH FLOW AND BALANCE SHEET 20 ACP Acquisition 3.6 2.8 3.3 2.8 3.0 Operating Cash Flow Leverage Ratio* ($ in millions) * Reconciliation to GAAP provided on slides 23 and 24 $53 $72 $54 $62 $81 2008 2009 2010 2011 2012
Slide 21: Key Investment Points
KEY INVESTMENT POINTS Compelling O&P industry growth dynamics Market leader in O&P patient care Proven organic growth and acquisition capabilities Solid financial position Steady margin enhancement Growth opportunities in adjacent markets 21
Slide 22: Appendix
150 YEARS Appendix of Empowering Human Potential.
Slide 23: Reconciliation of Non-GAAP Financial Measures
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES 23 Dollars in millions, except per share data 2009 2010 2011 2012 Adjusted EBITDA Reconciliation Income from Operations $ 90.5 $ 80.5 $ 116.0 $ 129.3 Depreciation & Amortization $ 16.3 $ 18.8 $ 31.0 $ 34.7 Relocation expenses - $ 16.4 $ 1.2 - Acquisition
Slide 24: Reconciliation of Non-GAAP Financial Measures
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES 24 Dollars in millions, except per share data 2011 2012 2013 2013 2013 Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Adjusted EBITDA Reconciliation Income from Operations $ 19.3 $ 32.9 $ 31.2 $ 32.5 $ 116.0 $ 21.7 $ 35.7 $ 35.4 $ 36.5 $ 129.3 $ 22.7 $ 36.6 $ 39